PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32384236-4	2020	We demonstrated that cRGD@dHA-c-DOX resulted in highly improved cellular uptake and cell death in MDA-MB-231 tumor cells (CD44 +, integrin alphavbeta3 +) compared to those in Huh7 tumor cells (CD44 -, integrin alphavbeta3 -).	Doxorubicin	32-35	integrin subunit alpha V	Homo sapiens	130-150	
18710273-0	2008	Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers.	Doxorubicin	35-46	integrin subunit alpha V	Homo sapiens	85-86	
18578486-0	2008	In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.	Doxorubicin	35-46	integrin subunit alpha V	Homo sapiens	111-131	
34977030-3	2021	Using a Cal27 tongue squamous cell carcinoma model, we have previously demonstrated that de novo expression of integrin alphaVbeta3 confers resistance to several anticancer drugs (cisplatin, mitomycin C and doxorubicin) through a mechanism involving downregulation of active Src, increased cell migration and invasion.	Doxorubicin	207-218	integrin subunit alpha V	Homo sapiens	111-131	
32384236-4	2020	We demonstrated that cRGD@dHA-c-DOX resulted in highly improved cellular uptake and cell death in MDA-MB-231 tumor cells (CD44 +, integrin alphavbeta3 +) compared to those in Huh7 tumor cells (CD44 -, integrin alphavbeta3 -).	Doxorubicin	32-35	integrin subunit alpha V	Homo sapiens	201-221	
27533248-4	2016	In the presence of the RGD motif, the Dox/P45 nanospheres could specifically target A549 cells, which have high integrin alphavbeta3 expression.	Doxorubicin	38-41	integrin subunit alpha V	Homo sapiens	112-132	
24757954-1	2014	A novel drug delivery system c(RGDyK)-modified Fe3O4 nanoparticles with high DOX load (R-DMP), which combines magnetic targeting, integrin alpha(v)beta3 targeting and high drug loading properties, was developed by chemical coupling both doxorubicin and peptide c(RGDyK) on the synthetic dual function magnetic nanoparticles (DMP) using a multi-hand cross-linker poly-L-glutamic acid.	Doxorubicin	77-80	integrin subunit alpha V	Homo sapiens	130-152	
24757954-1	2014	A novel drug delivery system c(RGDyK)-modified Fe3O4 nanoparticles with high DOX load (R-DMP), which combines magnetic targeting, integrin alpha(v)beta3 targeting and high drug loading properties, was developed by chemical coupling both doxorubicin and peptide c(RGDyK) on the synthetic dual function magnetic nanoparticles (DMP) using a multi-hand cross-linker poly-L-glutamic acid.	Doxorubicin	237-248	integrin subunit alpha V	Homo sapiens	130-152	
24757954-4	2014	Compare with those of doxorubicin coupled DMP without peptide c(RGDyK) modification, D-DMP shows enhanced uptake by integrin alpha(v)beta3 targeting expressing tumor cells and displays stronger cancer cell cytotoxicity.	Doxorubicin	22-33	integrin subunit alpha V	Homo sapiens	116-138	
23623323-0	2013	The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells.	Doxorubicin	57-68	integrin subunit alpha V	Homo sapiens	72-92	
23623323-7	2013	The prepared large size RGD-PEG-LP that targets the TECs via interacting with Integrin alphavbeta3, is a potentially effective and alternate therapeutic strategy for the treatment of DOX resistant tumor cells by utilizing DOX, in cases where Doxil is ineffective.	Doxorubicin	183-186	integrin subunit alpha V	Homo sapiens	78-98	
23623323-7	2013	The prepared large size RGD-PEG-LP that targets the TECs via interacting with Integrin alphavbeta3, is a potentially effective and alternate therapeutic strategy for the treatment of DOX resistant tumor cells by utilizing DOX, in cases where Doxil is ineffective.	Doxorubicin	222-225	integrin subunit alpha V	Homo sapiens	78-98	
24513318-3	2014	Herein, a pH-responsive charge-reversal polyelectrolyte and integrin alphaVbeta3 mono-antibody functionalized graphene oxide (GO) complex is constituted as a nanocarrier for targeted delivery and controlled release of DOX into cancer cells.	Doxorubicin	218-221	integrin subunit alpha V	Homo sapiens	60-80